These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 25454872)

  • 1. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
    van Dissel JT; Joosten SA; Hoff ST; Soonawala D; Prins C; Hokey DA; O'Dee DM; Graves A; Thierry-Carstensen B; Andreasen LV; Ruhwald M; de Visser AW; Agger EM; Ottenhoff TH; Kromann I; Andersen P
    Vaccine; 2014 Dec; 32(52):7098-107. PubMed ID: 25454872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.
    van Dissel JT; Soonawala D; Joosten SA; Prins C; Arend SM; Bang P; Tingskov PN; Lingnau K; Nouta J; Hoff ST; Rosenkrands I; Kromann I; Ottenhoff TH; Doherty TM; Andersen P
    Vaccine; 2011 Mar; 29(11):2100-9. PubMed ID: 21256189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.
    van Dissel JT; Arend SM; Prins C; Bang P; Tingskov PN; Lingnau K; Nouta J; Klein MR; Rosenkrands I; Ottenhoff TH; Kromann I; Doherty TM; Andersen P
    Vaccine; 2010 Apr; 28(20):3571-81. PubMed ID: 20226890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. H1:IC31 vaccination is safe and induces long-lived TNF-α
    Mearns H; Geldenhuys HD; Kagina BM; Musvosvi M; Little F; Ratangee F; Mahomed H; Hanekom WA; Hoff ST; Ruhwald M; Kromann I; Bang P; Hatherill M; Andersen P; Scriba TJ;
    Vaccine; 2017 Jan; 35(1):132-141. PubMed ID: 27866772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice.
    Liu X; Da Z; Wang Y; Niu H; Li R; Yu H; He S; Guo M; Wang Y; Luo Y; Ma X; Zhu B
    Vaccine; 2016 Mar; 34(11):1370-8. PubMed ID: 26845736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and protective efficacy of DMT liposome-adjuvanted tuberculosis subunit CTT3H vaccine.
    Teng X; Tian M; Li J; Tan S; Yuan X; Yu Q; Jing Y; Zhang Z; Yue T; Zhou L; Fan X
    Hum Vaccin Immunother; 2015; 11(6):1456-64. PubMed ID: 25905680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synchronization of dendritic cell activation and antigen exposure is required for the induction of Th1/Th17 responses.
    Kamath AT; Mastelic B; Christensen D; Rochat AF; Agger EM; Pinschewer DD; Andersen P; Lambert PH; Siegrist CA
    J Immunol; 2012 May; 188(10):4828-37. PubMed ID: 22504654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults.
    Luabeya AK; Kagina BM; Tameris MD; Geldenhuys H; Hoff ST; Shi Z; Kromann I; Hatherill M; Mahomed H; Hanekom WA; Andersen P; Scriba TJ; ; Schoeman E; Krohn C; Day CL; Africa H; Makhethe L; Smit E; Brown Y; Suliman S; Hughes EJ; Bang P; Snowden MA; McClain B; Hussey GD
    Vaccine; 2015 Aug; 33(33):4130-40. PubMed ID: 26095509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone.
    Thakur A; Pinto FE; Hansen HS; Andersen P; Christensen D; Janfelt C; Foged C
    Front Immunol; 2020; 11():803. PubMed ID: 32457748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells.
    Lindenstrøm T; Agger EM; Korsholm KS; Darrah PA; Aagaard C; Seder RA; Rosenkrands I; Andersen P
    J Immunol; 2009 Jun; 182(12):8047-55. PubMed ID: 19494330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder.
    Thakur A; Ingvarsson PT; Schmidt ST; Rose F; Andersen P; Christensen D; Foged C
    Vaccine; 2018 May; 36(23):3331-3339. PubMed ID: 29699790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll like-receptor agonist Pam
    Kennerknecht K; Noschka R; Löffler F; Wehrstedt S; Pedersen GK; Mayer D; Grieshober M; Christensen D; Stenger S
    Med Microbiol Immunol; 2020 Apr; 209(2):163-176. PubMed ID: 32020284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial.
    Geldenhuys H; Mearns H; Miles DJ; Tameris M; Hokey D; Shi Z; Bennett S; Andersen P; Kromann I; Hoff ST; Hanekom WA; Mahomed H; Hatherill M; Scriba TJ; ; van Rooyen M; Bruce McClain J; Ryall R; de Bruyn G;
    Vaccine; 2015 Jul; 33(30):3592-9. PubMed ID: 26048780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.
    Leroux-Roels I; Forgus S; De Boever F; Clement F; Demoitié MA; Mettens P; Moris P; Ledent E; Leroux-Roels G; Ofori-Anyinam O;
    Vaccine; 2013 Apr; 31(17):2196-206. PubMed ID: 22643213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of epitope recognition pattern in Ag85B and ESAT-6 has a profound influence on vaccine-induced protection against Mycobacterium tuberculosis.
    Bennekov T; Dietrich J; Rosenkrands I; Stryhn A; Doherty TM; Andersen P
    Eur J Immunol; 2006 Dec; 36(12):3346-55. PubMed ID: 17109467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
    Abraham S; Juel HB; Bang P; Cheeseman HM; Dohn RB; Cole T; Kristiansen MP; Korsholm KS; Lewis D; Olsen AW; McFarlane LR; Day S; Knudsen S; Moen K; Ruhwald M; Kromann I; Andersen P; Shattock RJ; Follmann F
    Lancet Infect Dis; 2019 Oct; 19(10):1091-1100. PubMed ID: 31416692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combined CTA1-DD/ISCOMs vector is an effective intranasal adjuvant for boosting prior Mycobacterium bovis BCG immunity to Mycobacterium tuberculosis.
    Andersen CS; Dietrich J; Agger EM; Lycke NY; Lövgren K; Andersen P
    Infect Immun; 2007 Jan; 75(1):408-16. PubMed ID: 17074845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liposome-based cationic adjuvant formulations (CAF): past, present, and future.
    Christensen D; Agger EM; Andreasen LV; Kirby D; Andersen P; Perrie Y
    J Liposome Res; 2009; 19(1):2-11. PubMed ID: 19515003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.